GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFMW) » Definitions » Debt-to-Revenue

Sunshine Biopharma (Sunshine Biopharma) Debt-to-Revenue : 0.02 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Sunshine Biopharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Sunshine Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.12 Mil. Sunshine Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.50 Mil. Sunshine Biopharma's annualized Revenue for the quarter that ended in Mar. 2024 was $30.16 Mil. Sunshine Biopharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.02.


Sunshine Biopharma Debt-to-Revenue Historical Data

The historical data trend for Sunshine Biopharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Debt-to-Revenue Chart

Sunshine Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.10 26.94 8.33 0.18 0.03

Sunshine Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.03 0.02 0.02

Competitive Comparison of Sunshine Biopharma's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Debt-to-Revenue falls into.



Sunshine Biopharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Sunshine Biopharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.119 + 0.539) / 24.093
=0.03

Sunshine Biopharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.115 + 0.497) / 30.164
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Sunshine Biopharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Biopharma (Sunshine Biopharma) Business Description

Traded in Other Exchanges
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).

Sunshine Biopharma (Sunshine Biopharma) Headlines